Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To select a better agent between S-1 or gemcitabine in combination with cisplatin for the
conventional chemotherapy platform for future development in advanced Biliary Tract
Adenocarcinoma (BTA), the investigators conduct a randomized phase II trial of S-1 and
cisplatin (SP) versus gemcitabine and cisplatin (GP) as first line therapy in advanced BTA.